Cargando…

VCP represses pathological cardiac hypertrophy

Detalles Bibliográficos
Autores principales:	Zhou, Ning, Stoll, Shaunrick, Qiu, Hongyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764385/ https://www.ncbi.nlm.nih.gov/pubmed/29283888 http://dx.doi.org/10.18632/aging.101357

Ejemplares similares

Novel genomic targets of valosin-containing protein in protecting pathological cardiac hypertrophy
por: Zhou, Ning, et al.
Publicado: (2020)

The valosin‐containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload
por: Zhou, Ning, et al.
Publicado: (2017)

DNA Methylation and Histone Modification in Hypertension
por: Stoll, Shaunrick, et al.
Publicado: (2018)

Functional Inhibition of Valosin-Containing Protein Induces Cardiac Dilation and Dysfunction in a New Dominant-Negative Transgenic Mouse Model
por: Sun, Xiaonan, et al.
Publicado: (2021)

Genomic characterization reveals novel mechanisms underlying the valosin-containing protein-mediated cardiac protection against heart failure
por: Zhou, Ning, et al.
Publicado: (2020)

Vascular smooth muscle cells direct extracellular dysregulation in aortic stiffening of hypertensive rats
por: Hays, Tristan T., et al.
Publicado: (2018)

Rho Kinase Regulates Aortic Vascular Smooth Muscle Cell Stiffness Via Actin/SRF/Myocardin in Hypertension
por: Zhou, Ning, et al.
Publicado: (2017)

Nuclear receptor corepressor 1 represses cardiac hypertrophy
por: Li, Chao, et al.
Publicado: (2019)

Inhibition of SRF/myocardin reduces aortic stiffness by targeting vascular smooth muscle cell stiffening in hypertension
por: Zhou, Ning, et al.
Publicado: (2017)

VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy
por: Cheng, Cheng, et al.
Publicado: (2022)

Neuronal VCP loss of function recapitulates FTLD-TDP pathology
por: Wani, Abubakar, et al.
Publicado: (2021)

Functions of Autophagy in Pathological Cardiac Hypertrophy
por: Li, Zhenhua, et al.
Publicado: (2015)

The Homozygote VCP(R155H/R155H) Mouse Model Exhibits Accelerated Human VCP-Associated Disease Pathology
por: Nalbandian, Angèle, et al.
Publicado: (2012)

Repression of Cardiac Hypertrophy by KLF15: Underlying Mechanisms and Therapeutic Implications
por: Leenders, Joost J., et al.
Publicado: (2012)

Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease
por: Ju, Jeong-Sun, et al.
Publicado: (2009)

Heterozygous mutations in valosin-containing protein (VCP) and resistance to VCP inhibitors
por: Bastola, Prabhakar, et al.
Publicado: (2019)

Increased afterload induces pathological cardiac hypertrophy: a new in vitro model
por: Hirt, Marc N., et al.
Publicado: (2012)

FYCO1 Increase and Effect of Arimoclomol–Treatment in Human VCP–Pathology
por: Guettsches, Anne-Katrin, et al.
Publicado: (2022)

The valosin-containing protein is a novel mediator of mitochondrial respiration and cell survival in the heart in vivo
por: Lizano, Paulo, et al.
Publicado: (2017)

Co-selected mutations in VCP: a novel mechanism of resistance to VCP inhibitors
por: Bastola, Prabhakar, et al.
Publicado: (2018)

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy
por: Yang, Dan, et al.
Publicado: (2022)

VCP takes out the trash
por: Short, Ben
Publicado: (2009)

VCP: VMware certified professional
por: Khnaser, Elias N
Publicado: (2009)

CIB1 is a Regulator of Pathological Cardiac Hypertrophy
por: Heineke, Joerg, et al.
Publicado: (2010)

Tripartite motif 32 prevents pathological cardiac hypertrophy
por: Chen, Lijuan, et al.
Publicado: (2016)

VCP VMware Certified Professional on vSphere 4 Study Guide, Exam VCP-410
por: Perry, Brian, et al.
Publicado: (2010)

VCP VMware certified professional vSphere 4 study guide: (exam VCP410)
por: Schmidt, Robert
Publicado: (2010)

Inactivation of VCP/ter94 Suppresses Retinal Pathology Caused by Misfolded Rhodopsin in Drosophila
por: Griciuc, Ana, et al.
Publicado: (2010)

Divergent and Overlapping Roles for Selected Phytochemicals in the Regulation of Pathological Cardiac Hypertrophy
por: Evans, Levi, et al.
Publicado: (2021)

VCP5 VMware Certified Professional on vSphere 5 Study Guide: Exam VCP-510
por: Atkinson, Brian
Publicado: (2012)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2016)

Caspase Cleavage of Gelsolin Is an Inductive Cue for Pathologic Cardiac Hypertrophy
por: Putinski, Charis, et al.
Publicado: (2018)

Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy
por: Fernandez-Caggiano, Mariana, et al.
Publicado: (2020)

The Role of CD147 in Pathological Cardiac Hypertrophy Is Regulated by Glycosylation
por: Zhong, Fang-yuan, et al.
Publicado: (2022)

Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy
por: Silva, Joana, et al.
Publicado: (2022)

ANGPTL8 is a negative regulator in pathological cardiac hypertrophy
por: Hu, Lin, et al.
Publicado: (2022)

Slowing Heart Rate Protects Against Pathological Cardiac Hypertrophy
por: Sebastian, Sonia, et al.
Publicado: (2022)

VCP suppresses proteopathic seeding in neurons
por: Zhu, Jiang, et al.
Publicado: (2022)

VCP-cloud official cert guide
por: Ralph, Tom, et al.
Publicado: (2013)

The Official VCP5 Certification Guide
por: Ferguson, Bill
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vfqpoob30drq1ht1a5vucv9jbd